• Abdel Moneim A. Physiology Division, Department of Zoology, Faculty of Science, Beni-Sueif University, Egypt
  • Morsy B. M. Biochemistry Division, Chemistry Department, Faculty of Science, Beni-Sueif University
  • Bo-seif M. A. Department of Internal Medicine, Faculty of Medicine, Beni-Sueif University
  • Zanaty M. I. Biochemistry Division, Chemistry Department, Faculty of Science, Beni-Sueif University


Chronic hepatitis C, Type 2 diabetes mellitus, Peginterferon and ribavirin


Objective:The present study aimed to determine whether type 2 diabetes mellitus influences the response to antiviral therapy with peg-interferon alpha plus ribavirin in Egyptian patients with chronic hepatitis C.

Methods:All patients were treated with peginterferon alpha 2 b (1.5 μg/Kg/body weight) subcutaneously plus oral ribavirin application in a dose ranging from 800-1200 mg/day and followed after 12 w of therapy.

Results: The present study indicated that, non-significant changes were observed in liver function, kidney function, thyroid function tests, tumor marker, immunological analysis, hematological parameters, viral load and degree of cirrhosis between both groups’ baselines, while the only significant difference was regarded in glucose level. However, diabetic group showed a significant decrease in response to antiviral therapy as compared to non-diabetic hepatitis C virus (HCV) patients. Furthermore, significant decrease in serum liver enzymes activity and total bilirubin level as compared to baseline levels in both groups, while there were a significant increase in alanine transaminase (ALT) activity and total bilirubin level in diabetic group as compared to non-diabetic HCV group after treatment. Also, significant decreases in hemoglobin concentration, white blood cells and platelet counts, in both groups after treatment as compared to there before treatment while diabetic group showed significant decreases in hemoglobin concentration and white blood cells count when compared with non-diabetic HCV group after treatment.

Conclusion: Type 2 diabetes mellitus influence the response to antiviral therapy with peginterferon plus ribavirin in Egyptian patients with chronic hepatitis C.


Download data is not yet available.


Mohd HK, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatol 2013; 57:1333–42.

Naggie S, Patel K, McHutchison J. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. J Antimicrob Chemother 2010;65:2063–9.

Senevirathna D, Amuduwage S, Weerasingam S, Jayasinghe S, Fernandopulle N. Hepatitis C virus in healthy blood donors in SriLanka. Asian J Trans Sci 2011;5:23-5.

El-Sadawy M, Ragab H. Hepatitis C virus infection at Sharkia Governorate, Egypt: seroprevalence and associated risk factors. J Egypt Soc Para 2004;34:367-84.

Jean M, Jean PB, Catherine GJ, Anne M. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001;35:279-83.

Negro F, Alaei M. Hepatitis C virus and type 2 diabetes . Gastroenterol 2009;15:1537-47.

Fabrizi F, Lampertico P, Lunghi G, Mangano S, Aucella F, Martin P. Hepatitis C virus infection and type 2 diabetes mellitus in renal diseases and transplantation. Aliment Pharmacol Ther 2005;21:623–32.

Younossi ZM. Specifically targeted antiviral therapy (STST-C) for patients with chronic hepatitis C. Medscape Business of Medicine. Am J Gastroenterol 2007;102:1672-6.

Suwantarat N, Tice AD, Khawcharoenporn T, Chow DC. Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to hepatitis C treatment. Int J Med Sci 2010;7:36–42.

Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroentrol 2003;124:1711-9.

Takaki S, Tsubota A, Hosaka T. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa 2 b and ribavirin combination therapy for chronic hepatitis C. J Gastroentrol 2004;39:668-73.

American Diabetes Association (ADA). Clinical practice recommendations. Diagnosis and classifications of diabetes mellitus; 2007;30:542-7.

Ghany MG, Doris B, Strader DB. Diagnosis, management and treatment of hepatitis C. Hepatol 2009;49:1335-74.

IFCC. Methods for the measurement of catalytic concentration of enzymes. J Clin Chem Clin Bio Chem 1983;18:521-34.

Tietz NW. Clinical Guide to Laboratory Tests. 3rd edition. Norbert W; 1995. p. 181-7.

Dasie SS, Lewis SM. Practical Hematology. 7 th edition. Churchil, Living Stone; 1991.

Choo QL, Weiner AJ. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull 1990;46:423-41.

Fraser CM. Compelete genomesequence of Treponema Pallidum, the syphilis spirochete. Science 1998;281:375.

Webster D. A study of the interaction of bromocresol green with isolated serum globulin fractions. Clin Chem 1974;53:109–15.

Loeliger EA, Van den Besselaar A. reliability and clinical impact of the prothrombin times in oral anticoagulant control. FK. Schattauer Velag. GmbH; 1985.

Murray RL. Clinical Chemistry. The C.V. Mosby Co. St. Louis. Toronto. Princeton; 1984. p. 1261-6, 418.

Forest MG, Pugeat M. Binding proteins of steroid Hormones colloque INSERM/John. Libbey Eurotext Ltd 1986;149:53-86.

Green ED, Baenziger JU. Asparagine-linked oligosaccharides on Lutropin, Follitropin and Thyrotropin. J Biochem 1988;263:25-35.

Emlen W, O'Neill L. Clinical significance of antinuclear antibodies: comparison detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum 1997;40:1612-8.

Hoshino ME, Camargo LC, Dasilv A. Standardization of hemagglutination test for schistosomiasis with formalin treated human erythrocyte. Tropic Hygiene 1980;19:463-70.

Farrell RJ, Smiddy PF, Pilkington RM. Guided versus blind liver biopsy for chronic hepatitis C: Clinical benefits and costs. J Hepatol 1999;30:580–7.

Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.

Nguyen MH, Keeffe EB, Pafait B. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005;3:97-101.

De Bruijne J, Buster EH, Gelderblom HC. Treatment of chronic hepatitis C virus infection-Dutch national guidelines. Neth J Med 2008;66:311-22.

Jacobson IM, Poordad F, Brown RS Jr, Kwo PY, Reddy KR, Schiff E. Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations. J Viral Hepatol 2012;19:236-43.

Imazeki F1, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus infected and hepatitis C virus cleared patients. Liver Int 2008;28:355-62.

Shiffman M, Schiff E, Pockros S. PF-03491390 (formerly IDN-6556),apancaspase inhibitor, is well-tolerated and effectively reduces raised aminotransferases (ALT and AST) in chronic active hepatitis C patients. 57th AASLD. Boston, MA; 2006. p. 27-31.

National Digestive Disease Information Clearing House. Chronic Hepatitis C Current Disease Management; 2010.

Zignego AL, Ferri C, Pileri SA, Bianchi FB. For the italian association of the study of liver (A. I. S. F.) commission on extrahepatic manifestations of HCV infection. A general over view and guidelines for a clinical approach. Dig Liver Dis 2006;39:2-17.

White A, Thurairajah PH, Thorburn D, Hubscher S, Lai WK, O'Donnell K, Mutimer D. Incidence and characterization elevations of serum transaminases in pegylated interferon and ribavirin treated patients with chronic hepatitis C. Aliment Pharmacol Ther 2007;25:1293-330.

Turbide C, Soulellis C, Deschênes M, Hilzenrat N. Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustain viral response? J Gastroenterol 2008;22:149-52.

Stintzing S, Schmitt C, Ocker M, Ganslmayer M, Zopf S, Gahr S, Hahn EG, et al. Liver function under interferon/ribavirin therapy of chronic hepatitis C. Germ Hepatogastroenterol 2009;56:462-5.

Romero-Gomez M, Del Mar VM, Andrade RJ. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterol 2006;128:636-41.

Shaukat A, Syed KH, Atiq RS. Chronic hepatitis C, response to interferon and ribavirin combination. Professional Med J 2010;17:563-7.

Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000;133:592–9.

Chen CB, Su WP, Peng CY, Lai HC, Liao KF, Huang WH, et al. Persistent transaminase elevations in chronic hepatitis C patients with virological response during peginterferon and ribavirin therapy. Hepatogastroenterol 2009;56:798-801.

Fried MW, Shiffman ML, Reddy KR, Smith C. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.

Alba LM, Nachnani JS, Rao GA, Bulchandani D, Pandya PK. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin. Ann Hematol 2010;89:121-5.

Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350-9.

Aspinall RJ, Pockros PJ. The management of side-effects during therapy for hepatitis C. Alim Pharmacol and Thera Div of Gastroenterol/Hepatol, USA; 2004;20:917-21.

Fried MW. Side effects of therapy of hepatitis C and their management. Hepatol 2001;36:237-44.

Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatol 2003;38:645-52.

Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatol 2002;36:128-34.

Chun-Hao C, Ming-Lung Y. Evolution of interferon-based therapy for chronic hepatitis C. Hepatitis Res Treat 2010;2010:1-12.

Poustchi H, Negro F, Hui J. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. Hepatol 2008;48:28–34.

Konishi I, Horiike N, Hiasa Y, Tokumoto Y, Michitaka K, Miyake Y, Nonaka S, et al. Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha 2b plus ribavirin therapy in patients with chronic hepatitis C. Hepatol Res 2007;37:331-6.

Bacon BR, Mc-Hutchison JG. Into the light: strategies for battling hepatitis C. Am J Managed Care 2007;13:319-26.

Nishiguchi S, Shiomi S, Nakatani S, Takeda T. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357:196-7.

Serhat A, David R, Lawrence E, David B. Impaired IRS-1/P13-kinase signaling in patients with HCV. A mechanism for the increased prevalence of type 2 diabetes.Hepatol 2003;38:1384-92.

Andrade RJ, Romero-Gomez, Diago M, Alonso A. Effect of sustain abnormal glucose values in virological response to treatment on the chronic hepatitis C. J Hepatol 2008;48:721-7.

Kaddai V, Negro F. Current understanding of insulin resistance in hepatitis C. Expert review of gastroenterology. Hepatol 2011;5:503-16.

Lonardo A, Adinolfi LE, Petta S, Craxi A, Loria P. Hepatitis C and diabetes the inevitable coincidence? Expert Rev Anti Infect Ther 2009;7:239-308.



How to Cite

A., A. M., M. B. M., B.- seif M. A., and Z. M. I. “THE EFFECTS OF DIABETES MELLITUS ON THE RESPONSE TO PEGINTERFERON-ALPHA IN COMBINATION WITH RIBAVIRIN THERAPY IN EGYPTIAN CHRONIC HEPATITIS C PATIENTS”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 11, Nov. 2015, pp. 27-34,



Original Article(s)